IP Verse

Safe And Effective Method Of Treating Ulcerative Colitis With Anti-Il12/Il23 Antibody - EP3883606B9

PatentPatent Analysis

EP3883606

JANSSEN BIOTECH
Application Number
EP19867085A
Filing Date
Sep 24, 2019
Status
Granted And Under Opposition
Jun 9, 2023
Grant Date
Nov 20, 2024
External Links
Slate, Register, Google Patents
Similar Patents facing opposition
EP3880824B1
EP2970980B2
EP3827845B1

Bibliography

The patent EP3883606B9 was granted to Janssen Biotech on Nov 20, 2024 following the initial filing on Sep 24, 2019 under the application number EP19867085A . The current legal status of the patent is Granted And Under Opposition.

AI Generated Summary New

Patent Family

Patent Family

Patent Oppositions (5)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

ACCORD HEALTHCAREApr 12, 2024WITHDRAWN
KARO PATENTANWALTE KAHLHOFER ROSSLER KREUELS PARTG MBBApr 11, 2024ADMISSIBLE
BIOCON BIOLOGICSApr 8, 2024WITHDRAWN
SAMSUNG BIOEPIS NLFeb 5, 2024ADMISSIBLE
CAMULONJul 27, 2023WITHDRAWN

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history, including filings, correspondence, and decisions made by patent offices. These documents are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination. It also includes the oppositions documents filed against the patent.

  • Date

    Description

  • Get instant alerts for new documents